CannaQ › Blog › Multiple sclerosis
DRAFT – not reviewedCannabinoids and multiple sclerosis: spasticity, pain and side effects
A 2022 Cochrane review of 25 randomised trials found moderate-certainty evidence for a short-term effect on spasticity with one THC/CBD spray, and much weaker evidence for other symptoms.
Key points
- A 2022 Cochrane review included 25 randomised trials with 3,763 adults with multiple sclerosis (MS).[1]
- In the review, nabiximols (a THC/CBD oromucosal spray) was associated with more people self-reporting an important reduction in spasticity than placebo over the short term (moderate-certainty evidence).[1]
- For chronic nerve pain and quality of life, the review authors were uncertain about any effect.[1]
- Cannabinoids may slightly increase stopping treatment because of side effects, and may increase nervous-system and psychiatric side effects (low certainty).[1]
The symptoms in question
Spasticity (muscle stiffness and spasms) and chronic neuropathic pain are common and serious symptoms of MS. They tend to increase as the disease progresses, and the review authors note that currently available treatments do not work well for everyone.[1] This article does not compare treatments; do not start, stop or change any MS treatment without talking to your healthcare team.
The 2022 Cochrane review
The review searched the literature up to December 2021 and included randomised trials of any cannabinoid in adults with MS.[1] The 25 trials lasted 3 to 48 weeks. Thirteen tested nabiximols, seven tested synthetic cannabinoids that mimic THC, and others tested an oral THC extract, dronabinol or inhaled herbal cannabis.[1]
| Outcome | Result vs placebo | Certainty |
|---|---|---|
| Important reduction in spasticity (nabiximols) | OR 2.51 (95% CI 1.56 to 4.04); about 216 more per 1,000 people reporting an important reduction in perceived spasticity; 5 trials, 1,143 participants | Moderate |
| Substantial relief of chronic neuropathic pain | Only one small trial (48 participants) of a synthetic cannabinoid; authors uncertain whether pain is reduced | Very low |
| Global impression "much" or "very much" improved | OR 1.80 (95% CI 1.37 to 2.36); 8 trials, 1,215 participants | Moderate |
| Health-related quality of life | May have little to no effect (SMD −0.08, 95% CI −0.17 to 0.02; 8 trials, 1,942 participants) | Low |
| Stopping treatment because of side effects | OR 2.41 (95% CI 1.51 to 3.84); about 39 more per 1,000; 21 trials, 3,110 participants | Low |
| Serious adverse events | Little to no difference (OR 1.38, 95% CI 0.96 to 1.99; 20 trials) | Low |
| Nervous-system side effects | May increase (OR 2.61, 95% CI 1.53 to 4.44) | Low |
| Psychiatric side effects | May increase (OR 1.94, 95% CI 1.31 to 2.88) | Low |
| Drug tolerance | Very uncertain | Very low |
OR = odds ratio; SMD = standardised mean difference; CI = confidence interval. Source: abstract of the Cochrane review.[1]
The authors concluded that the overall certainty of the evidence is limited by the short duration of the included studies.[1]
A closer look at one trial design
A phase 3 trial published in 2011 used an "enriched" design.[2] All 572 people enrolled first received nabiximols as an add-on for 4 weeks without a comparison group. Only those whose spasticity improved by at least 20% (272 people) could go on, and 241 were then randomised to continue nabiximols or switch to placebo for 12 weeks. In that second phase, spasticity scores favoured nabiximols (P=0.0002), as did several secondary outcomes, including spasm frequency and sleep disturbance.[2]
The authors explain that this design limits the comparison to people likely to benefit.[2] That is useful for some questions, but it also means the results do not describe what happens across all people with MS spasticity. About half of those enrolled did not reach the 20% improvement in the first phase.[2]
Limits of the evidence
- Most trials were short. Long-term benefits and harms are not well established.[1]
- The clearest finding concerns one product (nabiximols) and one symptom (spasticity), and it rests on people's own ratings of their symptoms.[1]
- Results for one cannabinoid product cannot be assumed to apply to others.
- One review author reported research grants from a pharmaceutical company for preclinical work and related patents. This is disclosed in the review.[1]
Ongoing research
On 2026-11-17, ClinicalTrials.gov listed three recruiting phase 2 trials of cannabis or cannabidiol in MS. They include a comparison of THC and CBD and a study of how cannabidiol relates to sleep and pain.[3,4,5]
References
All identifiers below were retrieved and checked on 2026-11-17 through PubMed E-utilities, the Europe PMC REST API and the ClinicalTrials.gov API v2.
- Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database Syst Rev. 2022;5(5):CD013444. PMID: 35510826. DOI: 10.1002/14651858.CD013444.pub2.
- Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122-1131. PMID: 21362108. DOI: 10.1111/j.1468-1331.2010.03328.x.
- ClinicalTrials.gov. Cannabis (THC vs. CBD) in Multiple Sclerosis. Phase 2; recruiting (checked 2026-11-17). NCT06261489.
- ClinicalTrials.gov. Cannabis as a Complementary Treatment in Multiple Sclerosis. Phase 2; recruiting (checked 2026-11-17). NCT05092191.
- ClinicalTrials.gov. Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype. Phase 2; recruiting (checked 2026-11-17). NCT05269628.